Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBVAXPRO with or without Hepatect in prior hepatitis B vaccine non-responders
ISRCTN84821453Phase 3Completed
- Sponsor
- Leipzig University
- Start
- Aug 2008
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatitis B (HBV) comparing HBVAXPRO alone with HBVAXPRO plus Hepatect (2 arms). Primary endpoint: Achievement of protective anti-HBs antibody titre. Started Aug 2008; status: completed.
02
Drugs
Recombivax HBhepatitis B immune globulin
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on ISRCTN84821453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN84821453.